Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 326

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1
Chunk 326
---
 our pre-clinical development activities.

Our
existing collaboration arrangements and any that we may enter into in the future may not be successful, which could adversely affect
our ability to develop and commercialize our product candidates.

We
have existing, and will likely continue to seek additional collaboration arrangements with pharmaceutical or biotechnology companies
for the manufacturing, testing, development or commercialization of our product candidates. We may, with respect to our product candidates,
enter into new arrangements on a selective basis depending on the merits of retaining commercialization rights for ourselves as compared
to entering into selective collaboration arrangements with leading pharmaceutical or biotechnology companies for each product candidate,
both in the U.S. and internationally. To the extent that we decide to enter into collaboration agreements, we will face significant competition
in seeking appropriate collaborators and the terms of any collaboration or other arrangements that we may establish may not be favorable
to us.

Any
existing or future collaboration entered into may not allow us to achieve our goals for such collaboration on a timely basis or at all.
Our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant
discretion in determining the efforts and resources that they will apply to these collaborations. Disagreements between parties to a
collaboration arrangement regarding development, intellectual property, regulatory or commercialization matters can lead to delays in
the development process or commercialization of the applicable product candidate and, in some cases, termination of the collaboration
arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority. Any such
termination or expiration could harm our business reputation and may adversely affect us financially.

39

We
depend on a limited number of suppliers for materials and components required to manufacture our product candidates. The loss of these
suppliers, or their failure to supply us on a timely basis, could cause delays in our current and future capacity and adversely affect
our business.

We
depend on a limited number of suppliers for the materials and components required to manufacture our product candidates. As a result,
we may not be able to obtain sufficient quantities of critical materials and components in the future. A delay or interruption by our
suppliers may also harm our business, results of operations and financial condition. In addition, the lead time needed to establish a
relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new
supplier. The time and effort to qualify for and, in some cases, obtain